These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
News & Analysis: MacroGenics
MacroGenics shares jumped in response to another major clinical update today.
These cancer drug developers could report market-moving news soon.
MGNX earnings call for the period ending March 31, 2019.
Positive results for its breast cancer drug candidate lit a fire under this small-cap biotech.
MGNX earnings call for the period ending December 31, 2018.
A positive breast cancer trial readout sent this tiny biotech's shares rocketing higher.
The cancer drug developer took a major hit, but here's why bargain hunters may want to take advantage of this opportunity.
MacroGenics' and Incyte Corp. team up in immuno-oncology.
Even though the market slumped, these stocks gained ground. Find out why.